跳至主要内容
临床试验/NCT03113656
NCT03113656已完成不适用

The Use of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome (NAS)

TriHealth Inc.2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2017年7月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
16
试验地点
2
主要终点
Change in Finnegan Score

研究概览

简要总结

Infants with neonatal abstinence syndrome (NAS) who are cared for in a Neonatal Intensive Care Unit (NICU) often display symptoms including hyperactivity, irritability, jitteriness, poor feeding, and poor sleep patterns. The recommended first line of treatment to relieve these symptoms involves nonpharmacological interventions. The purpose of the current pilot study is to provide preliminary data to assist in the design of a larger scale study to examine one nonpharmacological intervention, weighted blankets. The pilot study will assess the feasibility of a cross-over randomized controlled design to study the impact of a weighted blanket on infants' symptoms of NAS.

The aims of the study are:

Aim1: To determine the feasibility of recruiting patients for a study evaluating the use of weighted blankets in the care of infants with NAS Aim 2: To determine the feasibility and safety of the study procedures Aim 3: To examine whether there is clinical benefit to using weighted blankets for the treatment of symptoms in infants with NAS.

After informed consent is obtained, infants will be randomized to have either a weighted blanket or a non-weighted blanket placed on them first. A cross-over design will be used so all infants will experience both the non-weighted and weighted blankets. Thirty minutes before each feeding, baseline vital signs and Finnegan score will be obtained. Then, a blanket (weighted or non-weighted) will be placed on the infant for 30 minutes. Infants will be directly monitored and on heart rate/respiratory rate monitors while the blanket is applied. Vital signs and Finnegan scores will be obtained at the end of 30 minutes of blanket placement, infants will be fed, and vital signs and Finnegan scores will be obtained again 30 minutes after the blanket was removed. Descriptive statistics will be used to determine the enrollment rate and feasibility of the protocol. Nonparametric statistics will be used to compare total Finnegan scores for infants with the weighted blanket applied compared to infants with a non-weighted blanket applied. Changes in Finnegan scores will be examined to estimate an effect size to use in a power analysis for a future larger effectiveness study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
37 Weeks 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Admitted to the NICU
  • Gestational age > 37 weeks
  • Positive maternal drug screen at delivery

排除标准

  • Clinical staff does not give permission to enroll the patient
  • Had intrauterine growth restriction (IUGR)
  • Has any medical diagnosis in addition to NAS diagnosis
  • Has a weight below the 10th percentile

研究组 & 干预措施

Weighted Blanket First

Experimental

This group will receive the Weighted Blanket first and then the Non-weighted blanket

干预措施: Weighted Blanket (Other)

Weighted Blanket First

Experimental

This group will receive the Weighted Blanket first and then the Non-weighted blanket

干预措施: Non-Weighted Blanket (Other)

Non-weighted Blanket First

Experimental

This group will receive the Non-weighted Blanket first and then the Weighted blanket

干预措施: Weighted Blanket (Other)

Non-weighted Blanket First

Experimental

This group will receive the Non-weighted Blanket first and then the Weighted blanket

干预措施: Non-Weighted Blanket (Other)

结局指标

主要结局

Change in Finnegan Score

时间窗: baseline and 30 minutes

Finnegan scale measures signs of neonatal drug withdrawal syndrome. It provides a summative score obtained from the assessment of 21 items related to neonatal withdrawal. The total score ranges from 0 to 43 with a higher score indicating more severe symptoms. Values above 8 have been described as being indicative of neonatal abstinence syndrome.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rachel Baker

Nurse Researcher

TriHealth Inc.

研究点 (2)

Loading locations...

相似试验